An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects

Trial Profile

An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2014

At a glance

  • Drugs Perampanel (Primary)
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 10 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Oct 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Oct 2014.
    • 11 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top